Business
CytoSorbents Highlights Survival Benefit of CytoSorb Therapy in Septic Shock
MONMOUTH JUNCTION, N.J., Sept. 25, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb®
About this update from Cytosorbents Corporation
[{"type":"text","content":"MONMOUTH JUNCTION, N.J., Sept. 25, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights a new publication entitled, \"Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study,\" in the journal Critical Care.\n\n \nIn this study, clinical researchers at Maasstad Hospital and at Erasmus University Medical Center in Rotterdam, Netherlands conducted a retrospective evaluation of 116 patients with septic shock, who required vasopressors to increase their blood pressure, and renal replacement therapy (RRT) due to kidney failure. Of these, 49 patients received standard of care therapy, and 67 were treated with standard of care plus CytoSorb. Both groups were compared by stabilized Inverse Probability of Treatment Weights (sIPTW) to overcome baseline differences in the type of sepsis, age, comorbidities, surgery vs no surgery, Sequential Organ Failure Assessment (SOFA) score, use of the vasopressor noradrenaline, and lactate levels. \nPatients treated with standard of care and CytoSorb had a statistically significant reduction in 28-day all-cause mortality compared to standard of care alone (53% vs 72% control, p<0.04), based on the sIPTW analysis. In addition, observed 28-day all-cause mortality in the CytoSorb treatment group was significantly lower than the predicted mortality (48% observed vs 75% predicted, p<0.001), based on SOFA score. \nDr. Willem P. Brouwer, MD PhD, from Erasmus University Medical Center and Maasstad Hospital, and lead author of the study stated, \"To our knowledge, this study represents the largest published cohort of septic shock patients treated with CytoSorb therapy in which mortality was assessed as a primary outcome. We have demonstrated compelling evidence that CytoSorb, when added to standard continuous renal replacement therapy (CRRT), improved 28-day mortality in our patients with septic shock compared to CRRT alone. These findings significantly strengthen the current body of clinical evidence that demonstrate the benefit of CytoSorb in treating sepsis. The results are particu...